Key facts
- InEye Pharma’s last known valuation is $4.0M (Jul 2025).
- It has raised $790K; the latest was Later Stage VC ($690K) in Jul 2025.
- Notable investors include EIT Health, Insight Venture, Instituto Pedro Nunes, Portugal Ventures, Universidade de Coimbra.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for InEye Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for InEye Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InEye Pharma
Developer of medical devices designed to treat people suffering from eye diseases. The company's biomaterials and devices for ocular application are a mixture of drugs and polymers placed in the eye by the patient and are released simultaneously by simply adjusting their structure and composition, enabling healthcare professionals to help patients cure ocular and chronic eye diseases easily.
- Sector
- Healthcare
- HQ
- Coimbra, Portugal
- Founded
- 2017
- Employees
- 5
- Website
- ineyetherapeutics.com/
- Ownership
- Privately Held (backing)
InEye Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InEye Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InEye Pharma in its N-PORT filings yet. We sweep new filings monthly.